Please ensure Javascript is enabled for purposes of website accessibility

Why Bad COVID-19 News Didn't Stop the Nasdaq From Rising Tuesday

By Dan Caplinger - Updated Apr 13, 2021 at 2:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A setback in the vaccine fight had several big stocks gaining ground.

Tuesday was a mixed day for the stock market, but the Nasdaq Composite (^IXIC 0.00%) came out on top by midafternoon. The Nasdaq was up two-thirds of a percent as of 1:30 p.m. EDT today even as some other major market benchmarks remained down on the day.

Investors were surprised in 2020 when the Nasdaq was able to mount such a huge gain even during the worst of the pandemic. Those gains have reversed themselves very slightly in early 2021 as investors started to anticipate a return to more normal conditions in the economy. However, Tuesday's news regarding vaccines from Johnson & Johnson (JNJ -1.10%) appeared to give the stay-at-home stock niche a renewed boost of energy.

Four vials labeled COVID-19 vaccine.

Image source: Getty Images.

Big gains for last year's favorites

Many of the plays that worked best for much of 2020 were back in vogue on Tuesday afternoon. Zoom Video Communications (ZM 1.35%), which has played an increasingly vital role in sustaining levels of communication and collaboration during the pandemic, was up nearly 6% in early afternoon trading. Other software-as-a-service (SaaS) stocks showed similar resolve, with Atlassian (TEAM 2.70%) rising 4%, DocuSign (DOCU 2.77%) picking up 5%, and Okta (OKTA 1.62%) matching Zoom's 6% uptick.

Some other stay-at-home plays also showed signs of life. Peloton Interactive (PTON 13.60%) had fallen sharply in the past couple of months as optimism over reopening grew, but its stock was up more than 2% Tuesday amid new fears of prolonged coronavirus restrictions.

The catalyst came from the Food and Drug Administration and the Centers for Disease Control and Prevention, which recommended a pause in administering the one-dose vaccines developed by Johnson & Johnson. Rare blood clots appeared in a half-dozen cases, according to the regulators. That was sufficient to raise enough concerns to warrant the halt, in their opinion, despite the CDC's repeated statements about the deadly toll COVID-19 has taken and its urging Americans to get vaccinated.

What investors should expect

Even if the pause in J&J vaccines delays full implementation of vaccination programs by a month or two, that isn't long enough to justify a significant change in the valuation of any given stock. Big moves in shares of vaccine manufacturers like Moderna (MRNA -0.37%) make more sense because of how important the present is to their overall valuation.

But for Zoom, Peloton, and SaaS stocks in general, the much bigger question is how well their businesses will hold up once the pandemic is fully under control. Some worry about the disappearance of the tailwinds that have helped their businesses prosper over the past year, while others believe that clients will continue needing the services they provide regardless of the coronavirus situation.

Investors can expect both recovery plays and the Nasdaq stocks that did well last year to remain volatile for the time being. In the long run, though, their ability to prosper throughout the business cycle will determine whether their shares can keep rising or will give back their extensive gains.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Atlassian, DocuSign, Okta, Peloton Interactive, and Zoom Video Communications. The Motley Fool recommends Johnson & Johnson and Moderna Inc.. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoom Video Communications Stock Quote
Zoom Video Communications
ZM
$109.52 (1.35%) $1.46
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.30 (-1.10%) $-1.84
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$12,779.91 (0.00%) $0.00
Atlassian Corporation Plc Stock Quote
Atlassian Corporation Plc
TEAM
$283.25 (2.70%) $7.45
Okta Stock Quote
Okta
OKTA
$104.15 (1.62%) $1.66
DocuSign Stock Quote
DocuSign
DOCU
$74.34 (2.77%) $2.00
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63
Peloton Interactive, Inc. Stock Quote
Peloton Interactive, Inc.
PTON
$13.53 (13.60%) $1.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.